|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Zheng R, Zhang S, Zeng H, Wang S, Sun K,
Chen R, Li L, Wei W and He J: Cancer incidence and mortality in
China, 2016. J Natl Cancer Cent. 2:1–9. 2022.PubMed/NCBI
|
|
3
|
Arnold M, Soerjomataram I, Ferlay J and
Forman D: Global incidence of oesophageal cancer by histological
subtype in 2012. Gut. 64:381–387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baba Y, Yoshida N, Kinoshita K, Iwatsuki
M, Yamashita YI, Chikamoto A, Watanabe M and Baba H: Clinical and
prognostic features of patients with esophageal cancer and multiple
primary cancers: A retrospective single-institution study. Ann
Surg. 267:478–483. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang TX and Fu L: The immune landscape of
esophageal cancer. Cancer Commun (Lond). 39:792019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sihag S, Ku GY, Tan KS, Nussenzweig S, Wu
A, Janjigian YY, Jones DR and Molena D: Safety and feasibility of
esophagectomy following combined immunotherapy and
chemoradiotherapy for esophageal cancer. J Thorac Cardiovasc Surg.
161:836–843.e1. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kelly RJ: Immunotherapy for esophageal and
gastric cancer. Am Soc Clin Oncol Educ Book. 37:292–300. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qiao Y, Zhao C, Li X, Zhao J, Huang Q,
Ding Z, Zhang Y, Jiao J, Zhang G and Zhao S: Efficacy and safety of
camrelizumab in combination with neoadjuvant chemotherapy for ESCC
and its impact on esophagectomy. Front Immunol. 13:9532292022.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin GQ, Li ZL and Li D: The safety and
efficacy of neoadjuvant camrelizumab plus chemotherapy in patients
with locally advanced esophageal squamous cell carcinoma: A
retrospective study. Cancer Manag Res. 14:2133–2141. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zeng H, Chen W, Zheng R, Zhang S, Ji JS,
Zou X, Xia C, Sun K, Yang Z, Li H, et al: Changing cancer survival
in China during 2003-15: A pooled analysis of 17 population-based
cancer registries. Lancet Glob Health. 6:e555–e567. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Short MW, Burgers KG and Fry VT:
Esophageal cancer. Am Fam Physician. 95:22–28. 2017.PubMed/NCBI
|
|
12
|
Kitagawa Y, Uno T, Oyama T, Kato K, Kato
H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, et al:
Esophageal cancer practice guidelines 2017 edited by the Japan
esophageal society: Part 1. Esophagus. 16:1–24. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ajani JA, D'Amico TA, Bentrem DJ, Chao J,
Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, et
al: Esophageal and esophagogastric junction cancers, version
2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr
Canc Netw. 17:855–883. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van Hagen P, Hulshof MC, van Lanschot JJ,
Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ,
Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J
Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu
Z, Mao W, Xiang J, Han Y, Chen Z, et al: Neoadjuvant
chemoradiotherapy followed by surgery versus surgery alone for
locally advanced squamous cell carcinoma of the esophagus
(NEOCRTEC5010): A phase III multicenter, randomized, open-label
clinical trial. J Clin Oncol. 36:2796–2803. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Topalian SL, Drake CG and Pardoll DM:
Immune checkpoint blockade: A common denominator approach to cancer
therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gotwals P, Cameron S, Cipolletta D,
Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S,
Sabatos-Peyton C, Petruzzelli L, et al: Prospects for combining
targeted and conventional cancer therapy with immunotherapy. Nat
Rev Cancer. 17:286–301. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng Y, Wang Z, Yan C, Yan M, Hou Z,
Zheng R, Zhu Z and Li C: Protocol for a randomized controlled trial
of perioperative S-1 plus oxaliplatin combined with apatinib and
camrelizumab in patients with resectable, locally advanced gastric
or gastroesophageal junction adenocarcinoma. Ann Transl Med.
8:16842020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Y, Wang C, Li X, Dong L, Yang Q, Chen
M, Shi F, Brock M, Liu M, Mei Q, et al: Improved clinical outcome
in a randomized phase II study of anti-PD-1 camrelizumab plus
decitabine in relapsed/refractory Hodgkin lymphoma. J Immunother
Cancer. 9:e0023472021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang B, Qi L, Wang X, Xu J, Liu Y, Mu L,
Wang X, Bai L and Huang J: Phase II clinical trial using
camrelizumab combined with apatinib and chemotherapy as the
first-line treatment of advanced esophageal squamous cell
carcinoma. Cancer Commun (Lond). 40:711–720. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang W, Yan C, Gao X, Li X, Cao F, Zhao
G, Zhao J, Er P, Zhang T, Chen X, et al: Safety and feasibility of
radiotherapy plus camrelizumab for locally advanced esophageal
squamous cell carcinoma. Oncologist. 26:e1110–e1124. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Z, Lu X and Koral K: The clinical
application of camrelizumab on advanced hepatocellular carcinoma.
Expert Rev Gastroenterol Hepatol. 14:1017–1024. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hou X, Shi X and Luo J: Efficacy and
safety of camrelizumab (a PD-1 inhibitor) combined with
chemotherapy as a neoadjuvant regimen in patients with locally
advanced non-small cell lung cancer. Oncol Lett. 24:2152022.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Masterson L, Howard J, Gonzalez-Cruz J,
Jackson C, Barnett C, Overton L, Liu H, Ladwa R, Simpson F, McGrath
M, et al: Immune checkpoint inhibitors in advanced nasopharyngeal
carcinoma: Beyond an era of chemoradiation? Int J Cancer.
146:2305–2314. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou RQ, Luo J, Li LJ, Du M and Wu QC:
Neoadjuvant camrelizumab plus chemotherapy in locally advanced
oesophageal squamous cell carcinoma: A retrospective cohort study.
BMC Surg. 23:1142023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H,
Zhu L, Shen Y, Zhang H, Sun Y, et al: Multicenter, single-arm,
phase II trial of camrelizumab and chemotherapy as neoadjuvant
treatment for locally advanced esophageal squamous cell carcinoma.
J Immunother Cancer. 10:e0042912022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang W, Xing X, Yeung SJ, Wang S, Chen W,
Bao Y, Wang F, Feng S, Peng F, Wang X, et al: Neoadjuvant
programmed cell death 1 blockade combined with chemotherapy for
resectable esophageal squamous cell carcinoma. J Immunother Cancer.
10:e0034972022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang P, Zhou X, Yang X, Wang Y, Sun T,
Feng S and Ma X: Neoadjuvant camrelizumab plus chemotherapy in
treating locally advanced esophageal squamous cell carcinoma
patients: A pilot study. World J Surg Oncol. 19:3332021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu J, Li J, Lin W, Shao D, Depypere L,
Zhang Z, Li Z, Cui F, Du Z, Zeng Y, et al: Neoadjuvant camrelizumab
plus chemotherapy for resectable, locally advanced esophageal
squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2
study. Int J Cancer. 151:128–137. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qin J, Xue L, Hao A, Guo X, Jiang T, Ni Y,
Liu S, Chen Y, Jiang H, Zhang C, et al: Neoadjuvant chemotherapy
with or without camrelizumab in resectable esophageal squamous cell
carcinoma: The randomized phase 3 ESCORT-NEO/NCCES01 trial. Nat
Med. 30:2549–2557. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lavaud P, Bortolot M, Zullo L, O'Reilly D,
Naidoo J, Mountzios G, Mercier O, Hendriks LEL and Remon J:
Early-Stage non-small cell lung cancer: New challenges with immune
checkpoint blockers and targeted therapies. Cancers (Basel).
16:27792024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lei J, Zhao J, Gong L, Ni Y, Zhou Y, Tian
F, Liu H, Gu Z, Huang L, Lu Q, et al: Neoadjuvant camrelizumab plus
platinum-based chemotherapy vs chemotherapy alone for Chinese
patients with resectable stage IIIA or IIIB (T3N2) non-small cell
lung cancer: The TD-FOREKNOW randomized clinical trial. JAMA Oncol.
9:1348–1355. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shao M, Yao J, Wang Y, Zhao L, Li B, Li L,
Wu Z, Chen Z, Fan J and Qiu F: Two vs three cycles of neoadjuvant
sintilimab plus chemotherapy for resectable non-small-cell lung
cancer: neoSCORE trial. Signal Transduct Target Ther. 8:1462023.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun C, Liu Y, Zhang P, Wang X, Xu Y, Lin
X, Ma X, Guo Y, Qiu S, Shao G, et al: Interim analysis of the
efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab)
combined with chemotherapy (nab-paclitaxel and carboplatin) in
potentially resectable stage IIIA/IIIB non-small cell lung cancer:
A single-arm, phase 2 trial. J Cancer Res Clin Oncol. 149:819–831.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qiu Y, Su G, Zhang L, Fan H, Zhao H, Wang
C, Liu L, Chen B, Li X and Li S: Association between reactive
cutaneous capillary endothelial proliferation and the efficacy of
camrelizumab in esophageal cancer: A retrospective cohort study. J
Thorac Dis. 17:2453–2472. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song G, Zhang FF and Cheng HD: Thalidomide
for prevention of camrelizumab-induced reactive cutaneous capillary
endothelial proliferation. Australas J Dermatol. 63:217–221. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Q, Cao M, Yuan G, Cheng X, Zang M, Chen
M, Hu X, Huang J, Li R, Guo Y, et al: Lenvatinib Plus Camrelizumab
vs. Lenvatinib monotherapy as first-line treatment for unresectable
hepatocellular carcinoma: A multicenter retrospective cohort study.
Front Oncol. 12:8097092022. View Article : Google Scholar : PubMed/NCBI
|
